Jupiter Neurosciences IncJUNS
Price$2.55

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $21.8KTTM through 31 Dec 2025
Net Income -$8.6MTTM through 31 Dec 2025
Free Cash Flow -$5.4MTTM through 31 Dec 2025

Margins

Current
Gross Margin80.6%
Operating Margin-40,953.8%
Net Margin-39,662.8%

Returns

308.7%ROE
-155.4%ROA

Balance Sheet Health

Debt / Equity-1.73x
Net Debt$1M
Cash & Equivalents$3.8M

Quality Metrics

FCF Margin-24,838.2%
Earnings-Beat Rate25.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Premium Nutritional Supplements$21.8K
View details

Expanding commercial distribution channels and compounding pharmacy networks.

Pharmaceutical Operations$0
View details

Phase IIa RESET trial actively enrolling patients with first results anticipated in 2027.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.